

Table S2. Physical characteristics, fasting plasma lipids, and PCSK9 levels of 43 healthy volunteers (A) and 31 hypercholesterolemic subjects treated with statins (B) based on the V98L genotype. (mean \pm SD. P-values were obtained using a two-tailed Student's t-test. *, p=0.01. **, p=0.02. ***, p=0,001).

A

	AnxA2 V98L Non-carriers (min-max) n = 32	AnxA2 V98L heterozygotes (min-max) n = 10	AnxA2 V98L homozygotes (n = 1)
Age (years)	43 \pm 15 (21–76)	45 \pm 14 (25–67)	23
BMI (kg/m ²)	25.1 \pm 3.9 (19.5–35.2)	23.7 \pm 2.8 (18.9–28.1)	20.6
PCSK9 (ng/ml)	80.4 \pm 42.2 (25.9–190.2)	*56.1 \pm 20.9 (39.5–96.8)	38.0
TC (mmol/L)	5.37 \pm 0.82 (3.82–7.02)	5.66 \pm 1.79 (3.01-8.43)	3.79
TG (mmol/L)	1.37 \pm 0.89 (0.47–3.74)	1.43 \pm 0.71 (0.45–2.65)	0.53
LDLc (mmol/L)	3.11 \pm 0.84 (1.76–5.21)	3.34 \pm 1.43 (1.17–4.83)	1.94
HDLc (mmol/L)	1.62 \pm 0.45 (0.87–2.58)	1.49 \pm 0.29 (1.08–1.99)	1.61

B

	AnxA2 V98L Non-carriers (min-max) n = 25	AnxA2 V98L heterozygotes (min-max) n = 5	AnxA2 V98L homozygotes (n = 1)
Age (years)	55 \pm 17 (19–86)	65 \pm 18 (40–82)	59
BMI (kg/m ²)	26.0 \pm 3.9 (19.5–33.1)	27.1 \pm 5.8 (19.9–33.1)	24.4
PCSK9 (ng/ml)	106.4 \pm 37.8 (36.5–165.4)	112.1 \pm 12.3 (97.7–123.6)	41.5
TC (mmol/L)	4.93 \pm 0.95 (3.26–7.72)	**4.47 \pm 0.25 (4.08–4.71)	3.77
TG (mmol/L)	1.61 \pm 1.20 (0.54–5.65)	1.67 \pm 0.88 (0.93–3.00)	1.35
LDLc (mmol/L)	2.89 \pm 0.74 (1.62–4.76)	***2.27 \pm 0.18 (2.06–2.48)	2.06
HDLc (mmol/L)	1.35 \pm 0.38 (0.85–2.16)	1.38 \pm 0.53 (0.97–2.20)	1.09